K2 Therapeutics develops antibody-drug conjugates and T-cell engagers for cancer treatment, sourcing drug candidates globally.
$50MSeed
A $50M seed for a Singapore-based biotech is unusually large and signals that deep-tech oncology—especially cell therapy and ADCs—is attracting patient capital willing to fund longer timelines. If you're building in adjacent biotech (diagnostics, manufacturing, data tools), this validates that investors are still writing big checks for hard science, not just AI/software plays.